Biotech News

Ceasing to be a substantial holder

Mesoblast (MESO)Mesoblast2026-06-25 13:46 ESTCompany update

MESO (MESO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is meso.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

MESOMesoblast2026-06-30 23:56 EST

Receives FDA BLA Filing Number and Requests Modular Review

MESOMesoblast2026-06-29 22:13 EST

Becoming a substantial holder

MESOMesoblast2026-06-25 13:46 EST

Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility

MESOMesoblast2026-06-25 13:46 EST

Becoming a substantial holder

MESOMesoblast2026-06-25 13:46 EST

ASX CEO Connect Presentation

MESOMesoblast2026-06-25 13:46 EST

Mesoblast R&D Day Features Commercial & Blockbuster Programs

MESOMesoblast2026-06-25 13:46 EST

Mesoblast R&D Day Presentation

MESOMesoblast2026-06-25 13:46 EST

Acquires CAR Platform for Precision-Enhanced Cell Products

MESOMesoblast2026-06-25 13:46 EST

Application for quotation of securities - MSB

MESOMesoblast2026-06-25 13:46 EST

Notification regarding unquoted securities - MSB

View all latest news

Mesoblast

Mesoblast is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

MESOZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

MESOZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

MESOBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

MESOGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

MESOMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 16.22 USD
Market cap: 2B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States